- Home
- ZTEK vs SCPH Comparison
ZTEK vs SCPH Comparison
Compare ZTEK & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTEK
- SCPH
- Stock Information
- Founded
- ZTEK 2008
- SCPH 2013
- Country
- ZTEK Canada
- SCPH United States
- Employees
- ZTEK N/A
- SCPH N/A
- Industry
- ZTEK Major Chemicals
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- ZTEK Industrials
- SCPH Health Care
- Exchange
- ZTEK Nasdaq
- SCPH Nasdaq
- Market Cap
- ZTEK 165.9M
- SCPH 173.6M
- IPO Year
- ZTEK N/A
- SCPH 2017
- Fundamental
- Price
- ZTEK $1.52
- SCPH $3.64
- Analyst Decision
- ZTEK
- SCPH Strong Buy
- Analyst Count
- ZTEK 0
- SCPH 3
- Target Price
- ZTEK N/A
- SCPH $14.00
- AVG Volume (30 Days)
- ZTEK 51.2K
- SCPH 423.8K
- Earning Date
- ZTEK 06-26-2025
- SCPH 05-14-2025
- Dividend Yield
- ZTEK N/A
- SCPH N/A
- EPS Growth
- ZTEK N/A
- SCPH N/A
- EPS
- ZTEK N/A
- SCPH N/A
- Revenue
- ZTEK $44,936.00
- SCPH $41,982,000.00
- Revenue This Year
- ZTEK N/A
- SCPH $109.32
- Revenue Next Year
- ZTEK N/A
- SCPH $76.95
- P/E Ratio
- ZTEK N/A
- SCPH N/A
- Revenue Growth
- ZTEK 92.38
- SCPH 138.10
- 52 Week Low
- ZTEK $0.50
- SCPH $1.94
- 52 Week High
- ZTEK $1.84
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- ZTEK 51.88
- SCPH 66.63
- Support Level
- ZTEK $1.52
- SCPH $3.23
- Resistance Level
- ZTEK $1.62
- SCPH $3.74
- Average True Range (ATR)
- ZTEK 0.11
- SCPH 0.31
- MACD
- ZTEK -0.03
- SCPH 0.08
- Stochastic Oscillator
- ZTEK 34.98
- SCPH 93.81
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.